REFERENCES
1. Prazeres D, Ferreira G, Monteiro G, Cooney C, Cabral J. Large-scale production of pharmaceutical-grade plasmid DNA for
gene therapy. Trends Biotechnol. 1999;17(4):169–74.
2. Prather KJ, Sagar S, Murphy J, Chartrain M. Industrial scale production of plasmid DNA for vaccine and gene therapy: Plasmid
design, production and purification. Enzyme Microb Technol. 2003;33:865–83.
3. Schleef M, editor. Biotechnology. Volume 5a: Recombinant Proteins, Monoclonal antibodies and Therapeutic Genes. Hoboken,
NJ: Wiley & Sons; 1999. p. 445–69.
4. Vogel FR, Sarver H. Nucleic acid vaccines. Clin Microbiol. 1995;8:406–10.
5. Robinson HL. DNA vaccines. Clin Microbiol Newslett. 2000;23:17–22.
6. Herweijer H, Wolf J. Progress and prospects: Naked DNA gene transfer and therapy. Gene therapy. 2003;10:453–8.
7. Chattergoon M, Boyer J, Weiner DB. Gene immunization: A new era in vaccines and immune therapeutics. FASEB. 1997 Aug;11(10):753–63.
8. O'Kennedy R, Ward J, Keshavarz E. Effects of fermentation strategy on the characteristics of plasmid DNA production. Biotecnol
Appl Biochem. 2003 Feb;37 (Pt 1):83–90.
9. Kim B, Shuler M. Analysis of pBR322 replication kinetic and its dependency on growth rate. Biotechnol Bioeng. 1990;36:233–42.
10. Xu Z, LiuG, Cen P, Wong W. Factors influencing secretive production of human epidermal growth factor (hEGF) with recombinant
E. coli K12. Bioprocess Biosyst Eng. 2000;23:669–74.
11. Miller G. Anal. Chem. 1959 31:426–8.
12. Birnboim HC, Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res.
1979;7:1513–23.
13. Shiloach J, Fass R. Growing E. coli to high cell density—A historical perspective on method development. Biotechnol Adv.
2005;23:345–57.
14. Carnes A. Fermentation design for the manufacture of therapeutic plasmid DNA. BioProcess Int. 2005 Oct;3(9):36–44.
|
